Articles Referencing PCRX

Pacira Reports Wider Loss - Analyst Blog

5/10/2013, 9:24 am from Zacks.com in Investing, Business, Stocks

Pacira Pharmaceuticals, Inc. ( PCRX ) reported first quarter 2013 net loss per share of 60 cents, wider than the Zacks Consensus Estimate of a loss of 49 cents and the year-ago loss of 47... Read >>

Data on Pacira's Exparel - Analyst Blog

4/17/2013, 5:11 pm from Zacks.com in Investing, Business, Stocks

Pacira Pharmaceuticals, Inc. ( PCRX ) recently announced positive data from a phase IV study, EXCLAIM, evaluating the use of Exparel for postsurgical analgesia in patients undergoing four... Read >>

Pacira Prices Senior Notes - Analyst Blog

1/18/2013, 4:30 pm from Zacks.com in Investing, Business, Stocks

Pacira Pharmaceuticals, Inc. ( PCRX ) recently announced the pricing of its private offering of 3.25% convertible senior notes due Feb 1, 2019 worth $110 million. The offering is expected... Read >>

Pacira to Issue Notes - Analyst Blog

1/16/2013, 4:13 pm from Zacks.com in Investing, Business, Stocks

Pacira Pharmaceuticals, Inc. ( PCRX ) recently announced its intention to raise funds through the issuance of convertible senior notes due 2019 worth $100 million. Initial buyers will have... Read >>

FDA Watch: 6 Biotechs Awaiting FDA Drug Approvals in 2011

9/8/2011, 7:37 pm from Kapitall in Investing, Investing Ideas, Stocks

(Written by Alexander Crawford. FDA decision data sourced from RTT News, all other data sourced from Finviz.) 2011 has already been a solid year for FDA drug approvals. By late July, the FDA... Read >>